Medicare Coverage and Payment for Dialysis-Related Amyloidosis Treatments.
This law ensures Medicare covers specialized, FDA-approved treatments for individuals suffering from dialysis-related amyloidosis (DRA). The change guarantees that these critical treatments are paid for fully and separately from standard dialysis services, aiming to improve patient access to necessary care.
Key points
Medicare must now cover FDA-approved treatments specifically targeting dialysis-related amyloidosis when provided in a dialysis facility.
Payment for these specialized treatments will be made separately at 100% of reasonable charges, ensuring providers are fully reimbursed outside of the standard bundled dialysis rate.
Expired
Citizen Poll